Windtree to Present at the Ladenburg Thalmann Healthcare Conference

WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and will be available for in-person 1x1 meetings at the upcoming Ladenburg Thalmann Healthcare Conference taking place at the Sofitel Hotel in New York, NY on September 29, 2022.

To schedule a meeting with the Company, please contact your Ladenburg Thalmann representative.

A live webcast and replay will also be available under the Events section of the Company’s Investor relation website (https://ir.windtreetx.com/events).

About Windtree TherapeuticsWindtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

Contact Information:Monique KosseLifeSci Advisors212.915.3820 or [email protected]

Media contact:Katie Larch / Robert Flamm, Ph.D.Burns McClellan, Inc.[email protected] / [email protected]

You May Also Be Interested In

• Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
• Pension Deductions Announces Educational Resource Explaining How Cash Balance Plans Work for Doctors and Dentists
• From Lab to Life: How AI Works in China, Available August 4, Examines the Governance System Behind China's AI Industry